New York, New York -(Newsfile Corp. -January 23, 2025) – Why: Rosen Law Firm, a global investor rights law firm, is the purchaser of the common stock of Kyverna Therapeutics, Inc. the important February 7, 2025 Plaintiff Deadline.
so what: If you purchase Kyverna Common Stock, you may be entitled to compensation without paying any out-of-pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Kyverna class action, go to https://rosenlegal.com/submit-form/?case_id=32239 or call Phillip Kim, Esq. Toll-Free at 866-767-3653 or email case@rosenlegal.com for information about the class action. The class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the court No later than February 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select a qualified attorney with a proven track record of success in leadership roles. Often, companies issuing notices do not have similar experience, resources or any meaningful recognition of the decision. Many of these firms do not actually litigate securities class actions, but are simply brokers who refer clients or partner with law firms that actually prosecute cases. Be wise in choosing a lawyer. The Rosen Law Firm represents investors throughout the world, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest securities class action settlement against a Chinese company at that time. Rosen Law Firm is Ranked #1 by ISS Securities an act (WA:) services a number of securities class action settlements in 2017. The firm has been ranked in the top four every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company raised more than $438 million for investors. In 2020, co-founder Lawrence Rosen was named by Law360 as a Titan of Paintiffs'. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Case details: According to the lawsuit, the registration statement and prospectus used to malign Kyverna and/or omitted facts relating to the results of Kyverna's ongoing evaluation of KYV-101, Kyverna's lead product candidate, in clinical trials. Specifically, Kyverna described patient “improvement” in certain indications while disclosing no adverse data in connection with one of Kyverna's trials, for which negative data for Kyverna was known at the time of the IPO. When the true details entered the market, the lawsuit claims, investors suffered damages.
To join the Kyverna class action, go to https://rosenlegal.com/submit-form/?case_id=32239 or call Phillip Kim, Esq. Toll-Free at 866-767-3653 or email case@rosenlegal.com for information about the class action.
No chapter has been approved. Until a class is certified, you are not represented by an attorney unless you retain one. You can select the attorney of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to participate in any potential future recovery is not dependent on serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ https://www.facebook.com/rosenlawfirm/.
Advertisement lawyer. Previous results do not guarantee a similar result.
—————————
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238287
